Annual report pursuant to Section 13 and 15(d)

Note 2 - Acquisitions (Tables)

v3.7.0.1
Note 2 - Acquisitions (Tables)
12 Months Ended
Jun. 30, 2017
Notes Tables  
Business Acquisition, Pro Forma Information [Table Text Block]
 
 
Year Ended
 
 
 
June 30,
 
 
 
2017
 
 
2016
 
Net sales
  $
564,220
    $
523,840
 
Net income
   
99,380
     
110,536
 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
 
 
Zephyrus
 
 
Cliniqa
 
 
CyVek
 
 
Protein
Simple
 
 
Novus
 
                                         
Current assets
  $
56
    $
11,926
    $
1,206
    $
19,660
    $
10,739
 
Equipment
   
32
     
1,436
     
971
     
1,983
     
1,266
 
Other long-term assets
   
-
     
58
     
19
     
554
     
40
 
Intangible Assets:
                                       
Developed technology
   
8,300
     
18,000
     
20,200
     
39,200
     
5,010
 
Trade name
   
-
     
1,100
     
100
     
36,100
     
5,300
 
Customer relationships
   
-
     
27,000
     
600
     
101,600
     
14,400
 
Non-compete agreements
   
-
     
-
     
-
     
200
     
-
 
Goodwill
   
8,686
     
42,669
     
91,658
     
134,074
     
28,408
 
Total assets acquired
   
17,074
     
102,189
     
114,754
     
333,371
     
65,163
 
                                         
Liabilities
   
54
     
1,508
     
1,965
     
11,644
     
2,166
 
Deferred income taxes, net
   
2,521
     
17,793
     
(438
)
   
21,674
     
2,875
 
Net assets
   
14,500
     
82,888
     
113,227
     
300,053
     
60,122
 
Less fair-value of previous investment
   
-
     
-
     
18,300
     
-
     
-
 
Net assets acquired
  $
14,500
    $
82,888
    $
94,927
    $
300,053
    $
60,122
 
                                         
Cash paid, net of cash acquired
  $
8,000
    $
82,888
    $
59,927
    $
300,053
    $
60,122
 
Note Payable
   
-
     
-
     
-
     
-
     
-
 
Contingent consideration payable
   
6,500
     
-
     
35,000
     
-
     
-
 
Net purchase price
  $
14,500
    $
82,888
    $
94,927
    $
300,053
    $
60,122
 
Space [Member]  
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
 
 
Final
Opening
Balance Sheet
Allocation
 
Current assets, net of cash
  $
2,128
 
Equipment
   
159
 
Intangible assets:
       
Customer relationships
   
6,769
 
Goodwill
   
3,517
 
Total assets acquired
   
12,573
 
Liabilities
   
1,444
 
Deferred income taxes, net
   
2,125
 
Net assets acquired
  $
9,003
 
         
Cash paid, net of cash acquired
  $
6,747
 
Consideration payable
   
2,256
 
Net purchase price
  $
9,003
 
Advanced Cell Diagnostics (ACD) [Member]  
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
 
 
Preliminary
Allocation at
Acquisition
Date
 
 
Adjustments to
F
air Value
 
 
Updated Opening
Balance Sheet
Allocation at
June 30, 2017
 
Current assets, net of cash
  $
25,196
    $
(9,372
)
  $
15,824
 
Equipment
   
2,757
     
 
     
2,757
 
Other long-term assets
   
3,812
     
 
     
3,812
 
Intangible assets:
                       
Developed technology
   
107,000
     
43,000
     
150,000
 
Trade name
   
17,000
     
4,900
 
   
21,900
 
Customer relationships
   
77,000
     
(70,700
)
   
6,300
 
Non-compete agreement
   
200
     
(200
)
   
-
 
Goodwill
   
133,780
     
10,187
     
143,967
 
Total assets acquired
   
366,745
     
(22,185
)
   
344,560
 
Liabilities
   
3,591
     
588
     
4,179
 
Deferred income taxes, net
   
78,761
     
(26,018
)
   
52,743
 
Net assets acquired
  $
284,393
     
3,245
    $
287,638
 
                         
Cash paid, net of cash acquired
  $
246,193
     
845
    $
247,038
 
Consideration payable
   
-
     
3,600
     
3,600
 
Fair value contingent consideration
   
38,200
     
(1,200
)
   
37,000
 
Net purchase price
  $
284,393
     
3,245
    $
287,638